Literature DB >> 17828463

Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Keiko Maekawa1,2, Mayumi Saeki3, Yoshiro Saito4,3, Shogo Ozawa3,5, Kouichi Kurose3,6, Nahoko Kaniwa3,6, Manabu Kawamoto7, Naoyuki Kamatani7, Ken Kato8, Tetsuya Hamaguchi8, Yasuhide Yamada8, Kuniaki Shirao8, Yasuhiro Shimada8, Manabu Muto9, Toshihiko Doi10, Atsushi Ohtsu10, Teruhiko Yoshida11, Yasuhiro Matsumura12, Nagahiro Saijo13, Jun-Ichi Sawada4,3.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) is an inactivating and rate-limiting enzyme for 5-fluorouracil (5-FU), and its deficiency is associated with a risk for developing a severe or fatal toxicity to 5-FU. In this study, to search for genetic variations of DPYD encoding DPD in Japanese, the putative promoter region, all exons, and flanking introns of DPYD were sequenced from 341 subjects including cancer patients treated with 5-FU. Fifty-five genetic variations, including 38 novel ones, were found and consisted of 4 in the 5'-flanking region, 21 (5 synonymous and 16 nonsynonymous) in the coding exons, and 30 in the introns. Nine novel nonsynonymous SNPs, 29C>A (Ala10Glu), 325T>A (Tyr109Asn), 451A>G (Asn151Asp), 733A>T (Ile245Phe), 793G>A (Glu265Lys), 1543G>A (Val515Ile), 1572T>G (Phe524Leu), 1666A>C (Ser556Arg), and 2678A>G (Asn893Ser), were found at allele frequencies between 0.15 and 0.88%. Two known nonsynonymous variations reported only in Japanese, 1003G>T (*11, Val335Leu) and 2303C>A (Thr768Lys), were found at allele frequencies of 0.15 and 2.8%, respectively. SNP and haplotype distributions in Japanese were quite different from those reported previously in Caucasians. This study provides fundamental information for pharmacogenetic studies for evaluating the efficacy and toxicity of 5-FU in Japanese and probably East Asians.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828463     DOI: 10.1007/s10038-007-0186-6

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  35 in total

1.  Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH.

Authors:  T Nishiyama; K Ogura; H Okuda; K Suda; A Kato; T Watabe
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

2.  Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

Authors:  Z Lu; R Zhang; J T Carpenter; R B Diasio
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

3.  A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.

Authors:  Lori K Mattison; Martin R Johnson; Robert B Diasio
Journal:  Pharmacogenetics       Date:  2002-03

4.  Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.

Authors:  Martin R Johnson; Kangsheng Wang; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

5.  Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency.

Authors:  J A Bakkeren; R A De Abreu; R C Sengers; F J Gabreëls; J M Maas; W O Renier
Journal:  Clin Chim Acta       Date:  1984-07-31       Impact factor: 3.786

6.  Population study of dihydropyrimidine dehydrogenase in cancer patients.

Authors:  M C Etienne; J L Lagrange; O Dassonville; R Fleming; A Thyss; N Renée; M Schneider; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

Authors:  Z Lu; R Zhang; R B Diasio
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.

Authors:  Hui-Hua Hsiao; Ming-Yu Yang; Jan-Gowth Chang; Yi-Chang Liu; Ta-Chih Liu; Chao-Sung Chang; Tyen-Po Chen; Sheng-Fung Lin
Journal:  Cancer Chemother Pharmacol       Date:  2004-05       Impact factor: 3.333

9.  Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.

Authors:  Andrew X Zhu; Thomas A Puchalski; Vincent P Stanton; David P Ryan; Jeffrey W Clark; Steven Nesbitt; Olga Charlat; Patrick Kelly; Elaine Kreconus; Bruce A Chabner; Jeffrey G Supko
Journal:  Clin Colorectal Cancer       Date:  2004-02       Impact factor: 4.481

10.  Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.

Authors:  Hyun-Jung Cho; Young Suk Park; Won Ki Kang; Jong-Won Kim; Soo-Youn Lee
Journal:  Ther Drug Monit       Date:  2007-04       Impact factor: 3.681

View more
  16 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Authors:  Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yoshito Komatsu; Taroh Satoh; Masahiro Goto; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Naruhito Takenaka; Tadashi Hirooka; Kenichi Sugihara
Journal:  Glob Health Med       Date:  2020-08-31

3.  Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population.

Authors:  Eiji Hishinuma; Yoko Narita; Kai Obuchi; Akiko Ueda; Sakae Saito; Shu Tadaka; Kengo Kinoshita; Masamitsu Maekawa; Nariyasu Mano; Noriyasu Hirasawa; Masahiro Hiratsuka
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

4.  Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Rutger Meinsma; Veronika Schmid; Doreen Dobritzsch; Raoul C M Hennekam; Marcel M A M Mannens; Marion Kiechle; Marie-Christine Etienne-Grimaldi; Heinz-Josef Klümpen; Jan Gerard Maring; Veerle A Derleyn; Ed Maartense; Gérard Milano; Raymon Vijzelaar; Eva Gross
Journal:  Hum Genet       Date:  2010-08-29       Impact factor: 4.132

5.  Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.

Authors:  Joana Savva-Bordalo; João Ramalho-Carvalho; Manuela Pinheiro; Vera L Costa; Angelo Rodrigues; Paula C Dias; Isabel Veiga; Manuela Machado; Manuel R Teixeira; Rui Henrique; Carmen Jerónimo
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

6.  Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Authors:  K E Caudle; C F Thorn; T E Klein; J J Swen; H L McLeod; R B Diasio; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2013-08-29       Impact factor: 6.875

Review 7.  Colorectal cancer in Chinese patients: current and emerging treatment options.

Authors:  Leung Li; Brigette By Ma
Journal:  Onco Targets Ther       Date:  2014-10-04       Impact factor: 4.147

8.  Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.

Authors:  Eva Gross; Birgit Busse; Matthias Riemenschneider; Steffi Neubauer; Katharina Seck; Hanns-Georg Klein; Marion Kiechle; Florian Lordick; Alfons Meindl
Journal:  PLoS One       Date:  2008-12-23       Impact factor: 3.240

9.  Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.

Authors:  Joong-Gon Shin; Hyun Sub Cheong; Jason Yongha Kim; Lyoung Hyo Kim; Chang Soo Han; Ji On Kim; Hae Deun Kim; Young Hoon Kim; Myeon Woo Chung; Soon Young Han; Hyoung Doo Shin
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

10.  A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.

Authors:  S M Offer; A M Lee; L K Mattison; C Fossum; N J Wegner; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2013-04-03       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.